Cuprina Holdings Forms Joint Venture with Aiodine Laboratory to Develop Iodine-Based Wound Care Solution
Cuprina Holdings (Cayman) Ltd. has entered into a joint venture agreement with Singapore-based Aiodine Laboratory Pte Ltd. to develop, test, and market a novel iodine-based disinfectant solution for wound care and antiseptic applications. Under the agreement, Cuprina will oversee global sales, marketing, and distribution, while Aiodine Laboratory will provide proprietary iodine technology and technical expertise. The initial focus will be on wound care formulations, disinfectants, and daily antiseptics, with additional opportunities in personal care, oral hygiene, and veterinary applications under evaluation. Clinical studies for regulatory approval are planned to begin in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577846-en) on November 18, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。